MedTrace Logo

Effectiveness of Pramipexole for Treatment-Resistant Depression

NCT00231959 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2012-04-26

No results posted yet for this study

Summary

This study will evaluate the effectiveness of pramipexole (Mirapex) in managing treatment-resistant depression.

Conditions

Interventions

DRUG

Pramipexole (Mirapex)

pramipexole 0.5mg tablets qd and titrated per protocol

DRUG

Placebo

sugar pill

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Roy Perlis, MD · Massachusetts General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-09-30
Primary Completion
2007-09-30
Completion
2008-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00231959 on ClinicalTrials.gov